Applied Molecular Transport Book Value 2011-2026 | AMTI

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Applied Molecular Transport

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
60.8 M	164 M	132 M	-71.7 M	-44.1 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
164 M	-71.7 M	48.1 M

Quarterly Book Value Applied Molecular Transport

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
16.2 M	20.6 M	36.1 M	60.8 M	78.4 M	-	128 M	164 M	188 M	208 M	114 M	132 M	132 M	132 M	132 M	33.9 M	33.9 M	33.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
208 M	16.2 M	96.5 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	30.6 M	$ 2.11	-13.17 %	$ 217 M	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Apellis Pharmaceuticals APLS	370 M	$ 20.52	-2.12 %	$ 2.59 B	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Axsome Therapeutics AXSM	88.3 M	$ 164.13	0.15 %	$ 8.17 B	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Aytu BioScience AYTU	124 M	$ 2.49	-3.11 %	$ 15.6 M	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
BridgeBio Pharma BBIO	-2.08 B	$ 64.24	-3.37 %	$ 12.3 B	USA
BioAtla BCAB	70.7 M	$ 0.18	-26.92 %	$ 8.6 M	USA
BioCardia BCDA	-1.6 M	$ 1.37	6.2 %	$ 29 M	USA
BioCryst Pharmaceuticals BCRX	-476 M	$ 8.61	-1.66 %	$ 1.78 B	USA
Black Diamond Therapeutics BDTX	83.3 M	$ 2.4	-3.04 %	$ 132 M	USA
Beam Therapeutics BEAM	1.24 B	$ 28.29	-0.6 %	$ 2.8 B	USA
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-683 M	$ 11.47	-0.43 %	$ 742 M	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Biogen BIIB	18.3 B	$ 187.68	-2.16 %	$ 27.5 B	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
BioVie BIVI	19 M	$ 1.38	-0.01 %	$ 2.04 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	54.4 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
BioLineRx Ltd. BLRX	13.5 M	$ 2.91	2.83 %	$ 908 M	Israel
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
BioMarin Pharmaceutical BMRN	6.09 B	$ 60.68	-1.7 %	$ 11.6 B	USA
Bristol-Myers Squibb Company BMY	18.5 B	$ 62.54	0.27 %	$ 127 B	USA
Benitec Biopharma BNTC	97.3 M	$ 10.85	-0.5 %	$ 447 M	USA
BioNTech SE BNTX	19.4 B	$ 109.85	-0.34 %	$ 27.2 B	Germany
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
BioXcel Therapeutics BTAI	-93.1 M	$ 1.63	-2.69 %	$ 4.13 M	USA
Aptose Biosciences APTO	-4.54 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Burford Capital Limited BUR	1.66 B	$ 8.6	1.9 %	$ 1.39 B	Britain
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA